Ovarian Carcinosarcoma
Symptoms, Doctors, Treatments, Advances & More

Ovarian Carcinosarcoma Overview

Save information for later
Sign Up

Learn About Ovarian Carcinosarcoma

What is the definition of Ovarian Carcinosarcoma?
Ovarian carcinosarcoma, also known as a malignant mixed mullerian tumor (MMMT) of the ovary, is a rare, aggressive cancer of the ovary with characteristics of two types of cancer: carcinoma and sarcoma. Because women with this cancer often have no symptoms, more than half of women are diagnosed at an advanced stage. When present, symptoms may include pain in the abdomen or pelvic area, bloating or swelling of the abdomen, quickly feeling full when eating, or other digestive problems. The cause of Ovarian carcinosarcoma is not yet understood.
What are the alternative names for Ovarian Carcinosarcoma?
  • Ovarian carcinosarcoma
  • MMMT of the ovary
  • Malignant mixed Müllerian tumor of the ovary
  • Malignant mixed mullerian tumor of the ovary
  • Ovarian malignant mixed Müllerian tumor
  • Ovarian malignant mixed epithelial mesenchymal tumor
Who are the top Ovarian Carcinosarcoma Local Doctors?
Peter Rose
Elite in Ovarian Carcinosarcoma
Dr. Peter Rose
Surgical Oncology
Elite in Ovarian Carcinosarcoma
Dr. Peter Rose
Surgical Oncology

Cleveland Clinic Main Campus

10201 Carnegie Avenue, 
Cleveland, OH 
866-223-8100
Experience:
49+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Peter Rose is a Surgical Oncologist in Cleveland, Ohio. Dr. Rose has been practicing medicine for over 49 years and is rated as an Elite provider by MediFind in the treatment of Ovarian Carcinosarcoma. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Salpingo-Oophorectomy, and Hernia Surgery.

Scott Kamelle
Distinguished in Ovarian Carcinosarcoma
Dr. Scott Kamelle
Oncology
Distinguished in Ovarian Carcinosarcoma
Dr. Scott Kamelle
Oncology

Aurora Gynecologic Oncology

8905 W Lincoln Ave, Ste 407, 
West Allis, WI 
414-329-5656
Languages Spoken:
English
See accepted insurances

Scott Kamelle is an Oncologist in West Allis, Wisconsin. Dr. Kamelle is rated as a Distinguished provider by MediFind in the treatment of Ovarian Carcinosarcoma. His top areas of expertise are Endometrial Cancer, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Ureteroscopy, and Bladder Reconstruction.

 
 
 
 
Learn about our expert tiers
Learn More
Norman G. Rosenblum
Distinguished in Ovarian Carcinosarcoma
Dr. Norman G. Rosenblum
Oncology | Obstetrics and Gynecology
Distinguished in Ovarian Carcinosarcoma
Dr. Norman G. Rosenblum
Oncology | Obstetrics and Gynecology

Jefferson Obstetrics And Gynecology

833 Chestnut Street, 1st, Floor, 
Philadelphia, PA 
215-955-5000
Languages Spoken:
English
See accepted insurances

. Dr. Rosenblum is rated as a Distinguished provider by MediFind in the treatment of Ovarian Carcinosarcoma. His top areas of expertise are Endometrial Cancer, Vulvar Cancer, Sertoli-Leydig Cell Tumor, Hernia Surgery, and Hysterectomy.

View All Doctors
What are the latest Ovarian Carcinosarcoma Clinical Trials?
A Phase 1 Study of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
A Phase 1 Study of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
Enrollment Status: Recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug
Study Phase: Phase 1

Summary: This phase I trial tests the safety, side effects, and best dose of combination therapy with pelcitoclax (APG-1252) and cobimetinib in treating patients with ovarian and endometrial cancers that have come back after a period of improvement (recurrent). APG-1252 is a drug that inhibits activity of proteins that prevent cell death, leading to increased cell death and reduced cell growth. Cobimetinib...

Match to trials
Find the right clinical trials for you in under a minute
Get started
An International Multicentric Randomized Phase II Evaluating Dostarlimab in Combination With Niraparib Versus Niraparib Alone Compared to Chemotherapy in the Treatment of Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma After at Least One Line of Chemotherapy
An International Multicentric Randomized Phase II Evaluating Dostarlimab in Combination With Niraparib Versus Niraparib Alone Compared to Chemotherapy in the Treatment of Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma After at Least One Line of Chemotherapy
Who is this study for: Patients with metastatic or recurrent endometrial or ovarian carcinosarcoma after at least one line of chemotherapy
Enrollment Status: Recruiting
Publish Date: December 19, 2025
Intervention Type: Drug, Combination product
Study Drug: Niraparib
Study Phase: Phase 2/Phase 3

Summary: Carcinosarcomas (CS) (malignant mixed Müllerian tumors) are highly aggressive and rare tumors with a worldwide annual incidence between 0.5-3.3 cases/100.000 women. Gynecological CS, i.e. ovarian CS (OCS) and uterine CS (UCS), have a 5-year overall survival (OS) \< 10% and a poor prognosis. After initial treatment (surgery +/- adjuvant radiotherapies +/- chemotherapies (CT)), vast majority of pati...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center